Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Noninterventional Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Tumours (GEP-NETs) in Routine Clinical Practice

NCT03895463 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03895463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03895463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Noninterventional Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Tumours (GEP-NETs) in Routine Clinical Practice
Lead sponsor
Ipsen
Phase
Observational
Overall status
Withdrawn
Start date
August 31, 2019
Completion date
March 26, 2023
Enrollment
0 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors